Intarcia: Embattled Intarcia drug licensed to Harvard spinout, with Intarcia CEO Kurt Graves at the helm
Years after it went silent in the wake of multiple FDA rejections, Intarcia Therapeutics is effectively back.
Read full article »
Intarcia is a pharmaceutical company that develops and commercializes novel therapeutics for the treatment of chronic diseases.
Read more